PH26313A - Pharmaceutical compositions - Google Patents
Pharmaceutical compositions Download PDFInfo
- Publication number
- PH26313A PH26313A PH35433A PH35433A PH26313A PH 26313 A PH26313 A PH 26313A PH 35433 A PH35433 A PH 35433A PH 35433 A PH35433 A PH 35433A PH 26313 A PH26313 A PH 26313A
- Authority
- PH
- Philippines
- Prior art keywords
- ketotifen
- minutes
- per cent
- granulate
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 24
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 50
- 229960004958 ketotifen Drugs 0.000 claims description 49
- 239000008187 granular material Substances 0.000 claims description 42
- 239000000902 placebo Substances 0.000 claims description 19
- 229940068196 placebo Drugs 0.000 claims description 19
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 15
- 239000008101 lactose Substances 0.000 claims description 15
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000008206 lipophilic material Substances 0.000 claims description 4
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- 239000003925 fat Substances 0.000 description 26
- 210000002381 plasma Anatomy 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 238000000034 method Methods 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 229920002261 Corn starch Polymers 0.000 description 11
- 239000008120 corn starch Substances 0.000 description 11
- 239000001856 Ethyl cellulose Substances 0.000 description 10
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 229920001249 ethyl cellulose Polymers 0.000 description 10
- 235000019325 ethyl cellulose Nutrition 0.000 description 10
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 9
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000008203 oral pharmaceutical composition Substances 0.000 description 8
- 239000008385 outer phase Substances 0.000 description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 239000007888 film coating Substances 0.000 description 5
- 238000009501 film coating Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- -1 glyceryl fatty acid esters Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical class CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- PQHQBRJAAZQXHL-UHFFFAOYSA-N 2c-i Chemical compound COC1=CC(CCN)=C(OC)C=C1I PQHQBRJAAZQXHL-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010016948 Food interaction Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920003095 Methocel™ K15M Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3620830 | 1986-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26313A true PH26313A (en) | 1992-04-23 |
Family
ID=6303418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH35433A PH26313A (en) | 1986-06-21 | 1987-06-19 | Pharmaceutical compositions |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US5399360A (sv) |
| JP (2) | JPS638332A (sv) |
| KR (1) | KR880000095A (sv) |
| AT (1) | AT400521B (sv) |
| AU (1) | AU611637B2 (sv) |
| BE (1) | BE1000661A4 (sv) |
| CA (1) | CA1314227C (sv) |
| CH (3) | CH676201A5 (sv) |
| CY (1) | CY1589A (sv) |
| DE (1) | DE3719818C2 (sv) |
| DK (1) | DK314387A (sv) |
| ES (1) | ES2006170A6 (sv) |
| FI (1) | FI872733A (sv) |
| FR (1) | FR2600253B1 (sv) |
| GB (1) | GB2191696B (sv) |
| GR (1) | GR870965B (sv) |
| HK (1) | HK27691A (sv) |
| HU (1) | HU202753B (sv) |
| IE (1) | IE59178B1 (sv) |
| IL (1) | IL82924A (sv) |
| IT (1) | IT1216822B (sv) |
| LU (1) | LU86928A1 (sv) |
| MY (1) | MY101566A (sv) |
| NL (1) | NL8701335A (sv) |
| NO (1) | NO872551L (sv) |
| NZ (1) | NZ220769A (sv) |
| PH (1) | PH26313A (sv) |
| PT (1) | PT85128B (sv) |
| SE (1) | SE8702563L (sv) |
| ZA (1) | ZA874450B (sv) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5891460A (en) * | 1995-06-07 | 1999-04-06 | University Of Southern California University Park Campus | Method for reducing or preventing post-surgical adhesion formation using ketotifen and analogs thereof |
| EP1014979A4 (en) * | 1997-06-09 | 2003-08-20 | Bridge Pharma Inc | CONNECTIONS WITH COMBINED ANTIHISTAMINIC AND FAST-CELL STABILIZING ACTIVITY FOR OPHTHALMOLOGICAL USE |
| US6740889B1 (en) * | 1998-09-28 | 2004-05-25 | Applied Materials, Inc. | Charged particle beam microscope with minicolumn |
| AU5139800A (en) * | 1999-12-01 | 2001-06-12 | Klein Pharmaceuticals | Topical administration of ketotifen |
| US20030153620A1 (en) | 2000-05-12 | 2003-08-14 | Meakin Timothy David | Treating eczema and/or psoriasis |
| NZ514536A (en) * | 2001-09-28 | 2005-02-25 | Meracol Corp Ltd | Use of cetyl myristate and/or cetyl palmitate to treat asthma, chronic obstructive pulmonary disease and/or other respiratory difficulties |
| ITMI20012366A1 (it) * | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
| JP4867128B2 (ja) * | 2002-10-01 | 2012-02-01 | 大正製薬株式会社 | 経口鼻炎治療用組成物 |
| US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
| US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| AU2005320547B2 (en) * | 2004-12-27 | 2009-02-05 | Eisai R & D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
| US20100166804A1 (en) * | 2007-05-23 | 2010-07-01 | Dennis Penn | Methods |
| WO2009142772A2 (en) * | 2008-05-23 | 2009-11-26 | Mastcell Pharmaceuticals, Inc. | Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
| EP2441445A1 (en) * | 2010-10-14 | 2012-04-18 | Deva Holding Anonim Sirketi | Coating of cetyl myristate and/or cetyl palmitate particles |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH531000A (de) * | 1970-03-11 | 1972-11-30 | Sandoz Ag | Verfahren zur Herstellung neuer Benzocycloheptathiophene |
| DE2360796B2 (de) * | 1973-12-06 | 1977-06-02 | Edelfettwerke Werner Schlüter, 2000 Hamburg; Glyco Iberica S.A., Gava, Barcelona (Spanien) Vti: Hegel, K.Th., Dr.; Dickel, K., Dipl.-Ing.; Pat.-Anwälte, 2000 Hamburg und 8000 München | Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm |
| DE2426811A1 (de) * | 1974-06-04 | 1976-01-08 | Klinge Co Chem Pharm Fab | Verfahren zur herstellung von retard-tabletten |
| US4073915A (en) * | 1975-05-20 | 1978-02-14 | Sandoz Ltd. | Treating asthma |
| JPS51142543A (en) * | 1975-05-20 | 1976-12-08 | Sandoz Ag | Improvement in organic compound |
| FR2440371A1 (fr) * | 1978-10-31 | 1980-05-30 | Fisons Ltd | Nouveaux composes azotes heterocycliques, des compositions pharmaceutiques en contenant et des procedes pour les preparer |
| GB2154874B (en) * | 1984-02-29 | 1987-11-04 | Sandoz Ltd | Bromoscriptine compositions |
| KR920010392B1 (ko) * | 1984-03-01 | 1992-11-27 | 산도즈 아크리엔 게젤샤프트 | 경피투여용 약학 조성물의 제조방법 |
| DE3421468A1 (de) * | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung |
| IT1200102B (it) * | 1984-08-16 | 1989-01-05 | Sandoz Ag | Preparazioni farmaceutiche comprendenti chetotifere ed una xartina ad azione antiasmatica in combinazione fissa |
| US5069911A (en) * | 1985-02-05 | 1991-12-03 | Sandoz Ltd. | Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions |
| DE3505433A1 (de) * | 1985-02-16 | 1986-08-21 | Basf Ag, 6700 Ludwigshafen | Direkttablettierhilfsmittel |
| FR2581541B1 (fr) * | 1985-05-09 | 1988-05-20 | Rhone Poulenc Sante | Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation |
| US4797286A (en) * | 1985-11-12 | 1989-01-10 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulations |
| US4798725A (en) * | 1986-06-16 | 1989-01-17 | Norwich Eaton Pharmaceuticals, Inc. | Sustained release capsule |
-
1987
- 1987-06-09 HU HU872627A patent/HU202753B/hu unknown
- 1987-06-09 NL NL8701335A patent/NL8701335A/nl not_active Application Discontinuation
- 1987-06-13 DE DE3719818A patent/DE3719818C2/de not_active Expired - Lifetime
- 1987-06-15 MY MYPI87000814A patent/MY101566A/en unknown
- 1987-06-16 CH CH1925/89A patent/CH676201A5/de not_active IP Right Cessation
- 1987-06-16 CH CH2267/87A patent/CH672735A5/de not_active IP Right Cessation
- 1987-06-17 ES ES8701784A patent/ES2006170A6/es not_active Expired
- 1987-06-17 GB GB8714131A patent/GB2191696B/en not_active Expired - Lifetime
- 1987-06-18 FI FI872733A patent/FI872733A/fi not_active Application Discontinuation
- 1987-06-18 FR FR878708505A patent/FR2600253B1/fr not_active Expired - Lifetime
- 1987-06-18 NO NO872551A patent/NO872551L/no unknown
- 1987-06-18 BE BE8700679A patent/BE1000661A4/fr not_active IP Right Cessation
- 1987-06-18 SE SE8702563A patent/SE8702563L/sv not_active Application Discontinuation
- 1987-06-19 IE IE163487A patent/IE59178B1/en not_active IP Right Cessation
- 1987-06-19 PH PH35433A patent/PH26313A/en unknown
- 1987-06-19 AU AU74525/87A patent/AU611637B2/en not_active Ceased
- 1987-06-19 IL IL82924A patent/IL82924A/xx not_active IP Right Cessation
- 1987-06-19 GR GR870965A patent/GR870965B/el unknown
- 1987-06-19 CA CA000540178A patent/CA1314227C/en not_active Expired - Lifetime
- 1987-06-19 AT AT0156187A patent/AT400521B/de not_active IP Right Cessation
- 1987-06-19 ZA ZA874450A patent/ZA874450B/xx unknown
- 1987-06-19 DK DK314387A patent/DK314387A/da not_active Application Discontinuation
- 1987-06-19 PT PT85128A patent/PT85128B/pt unknown
- 1987-06-19 LU LU86928A patent/LU86928A1/fr unknown
- 1987-06-19 NZ NZ220769A patent/NZ220769A/en unknown
- 1987-06-19 IT IT8748075A patent/IT1216822B/it active
- 1987-06-20 JP JP62154265A patent/JPS638332A/ja active Pending
- 1987-06-20 KR KR1019870006312A patent/KR880000095A/ko not_active Application Discontinuation
-
1989
- 1989-06-16 CH CH1924/89A patent/CH674805A5/de not_active IP Right Cessation
-
1991
- 1991-04-11 HK HK276/91A patent/HK27691A/xx not_active IP Right Cessation
-
1992
- 1992-04-03 CY CY1589A patent/CY1589A/xx unknown
- 1992-09-07 JP JP4238166A patent/JP2860013B2/ja not_active Expired - Lifetime
-
1993
- 1993-08-11 US US08/105,532 patent/US5399360A/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5399360A (en) | Pharmaceutical compositions | |
| US5439687A (en) | Dosage forms having zero-order dihydropyridine calcium antagonist release | |
| CA2795324C (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| JP2006096771A (ja) | 制御放出モルヒネ製剤 | |
| WO2009034541A2 (en) | Controlled release pharmaceutical dosage forms of trimetazidine | |
| WO2010128525A2 (en) | A formulation of ivabradine for treating the cardiovascular disease | |
| CA2415154C (en) | Modified release formulations of selective serotonin re-uptake inhibitors | |
| ZA200101894B (en) | Method for preparing novel fenofibrate galenic formulations, galenic formualtions obtained and applications. | |
| CN115518066A (zh) | 一种用于治疗抗凝血的药物组合物及应用 | |
| US8105627B2 (en) | Extended release venlafaxine tablet formulation | |
| JP2005537221A (ja) | トラマドールの徐放性製剤 | |
| PT85880B (pt) | Processo para a preparacao de composicoes farmaceuticas de accao retardada contendo como substancia veicular uma mistura de celulose microcristalina com hidroxipropil-metilcelulose | |
| JP6866136B2 (ja) | デュロキセチン塩酸塩を含む口腔内崩壊錠 | |
| JP2001511450A (ja) | チアガビンを含有する制御放出性の医薬組成物 | |
| WO2005065662A1 (en) | Solid dosage formulations of galantamine | |
| EP0557244B1 (en) | Dosage forms having prolonged active-ingredient release | |
| KR950007229B1 (ko) | 케토티펜을 함유한 약학적 조성물 | |
| EP3727344A1 (en) | Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin | |
| AU598751B2 (en) | Pharmaceutical formulations with controlled release of the active substance | |
| WO2024200335A1 (en) | Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32 h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide | |
| IE862565L (en) | Controlled release pharmaceutical | |
| EP1713451A1 (en) | Solid dosage formulations of galanthamine |